Zacks: Analysts Expect Tetraphase Pharmaceuticals Inc (TTPH) Will Announce Quarterly Sales of $2.26 Million
Equities analysts expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to post $2.26 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $3.28 million. Tetraphase Pharmaceuticals reported sales of $1.09 million during the same quarter last year, which indicates a positive year-over-year growth rate of 107.3%. The company is scheduled to report its next quarterly earnings report on Wednesday, March 14th.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $2.26 million for the current year, with estimates ranging from $6.00 million to $10.41 million. For the next financial year, analysts forecast that the company will report sales of $6.58 million per share, with estimates ranging from $5.00 million to $12.41 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm had revenue of $4.10 million during the quarter, compared to the consensus estimate of $1.59 million. During the same period last year, the business posted ($0.58) EPS. Tetraphase Pharmaceuticals’s quarterly revenue was up 355.6% on a year-over-year basis.
Tetraphase Pharmaceuticals (TTPH) opened at $6.24 on Thursday. Tetraphase Pharmaceuticals has a one year low of $3.57 and a one year high of $9.93. The firm has a market capitalization of $320.83, a P/E ratio of -2.17 and a beta of 2.51.
In related news, Director L Patrick Gage purchased 3,880 shares of the company’s stock in a transaction on Wednesday, November 29th. The stock was bought at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jacques Dumas sold 7,167 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $6.21, for a total value of $44,507.07. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in TTPH. SG Americas Securities LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter worth $107,000. Brighton Jones LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter worth $108,000. AXA purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth $132,000. Virtu KCG Holdings LLC purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth $147,000. Finally, Voya Investment Management LLC increased its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 3,104 shares in the last quarter. 58.15% of the stock is owned by institutional investors.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.